Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision therapies for degenerative eye conditions, beginning with age-related macular ...

Character Biosciences is entering the clinic with a trove of company-generated human data already in hand. These data inform Character’s approach to targets for the dry form of age-related ...

Character Biosciences has landed a $93 million series B to progress its precision medicine candidates through clinical development. The round was led by new investors aMoon and Luma Group ...

Funding will enable lead candidates CTX114 and CTX203 for AMD to enter clinical trials in the next year JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences, a precision medicine company ...

Character Biosciences announced this week it completed a $93 million Series B financing round. The Jersey City-based company develops targeted therapies for progressive polygenic diseases.